{"parse":{"title":"Protandim","pageid":12155777,"revid":860195882,"text":{"*":"<div class=\"mw-parser-output\"><div class=\"shortdescription nomobile noexcerpt noprint searchaux\" style=\"display:none\">American multi-level marketing company</div>\n<p><b>Protandim</b> is a herbal <a href=\"/wiki/Dietary_supplement\" title=\"Dietary supplement\">dietary supplement</a> marketed with unsupported claims that it can treat a number of medical conditions. The product is a <a href=\"/wiki/Patent_medicine\" title=\"Patent medicine\">patented</a><sup id=\"cite_ref-Patent1_1-0\" class=\"reference\"><a href=\"#cite_note-Patent1-1\">&#91;1&#93;</a></sup> mix of five herbal ingredients and sold by LifeVantage Corporation (formerly LifeLine Therapeutics, Lifeline Nutraceuticals, and Yaak River Resources, Inc), a <a href=\"/wiki/Utah\" title=\"Utah\">Utah</a>-based <a href=\"/wiki/Multi-level_marketing\" title=\"Multi-level marketing\">multi-level marketing</a> company.<sup id=\"cite_ref-LifeVantage_2-0\" class=\"reference\"><a href=\"#cite_note-LifeVantage-2\">&#91;2&#93;</a></sup> The manufacturers of Protandim claim it can prevent or cure a wide variety of medical conditions, including diabetes and cancer.<sup id=\"cite_ref-sbm2017_3-0\" class=\"reference\"><a href=\"#cite_note-sbm2017-3\">&#91;3&#93;</a></sup> In 2017, LifeVantage was issued a <a href=\"/wiki/FDA_warning_letter\" title=\"FDA warning letter\">warning letter</a> by the U.S. Food and Drug Administration (FDA) regarding illegal advertising claims on the company\u2019s websites suggesting that Protandim can help to cure various ailments, including cancer and diabetes.<sup id=\"cite_ref-SLT_042617_4-0\" class=\"reference\"><a href=\"#cite_note-SLT_042617-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-SBN_5-0\" class=\"reference\"><a href=\"#cite_note-SBN-5\">&#91;5&#93;</a></sup><sup id=\"cite_ref-fda0417_6-0\" class=\"reference\"><a href=\"#cite_note-fda0417-6\">&#91;6&#93;</a></sup>\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#History\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">History</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-2\"><a href=\"#Product_invention\"><span class=\"tocnumber\">1.1</span> <span class=\"toctext\">Product invention</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-3\"><a href=\"#Composition\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Composition</span></a></li>\n<li class=\"toclevel-1 tocsection-4\"><a href=\"#Effectiveness\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Effectiveness</span></a></li>\n<li class=\"toclevel-1 tocsection-5\"><a href=\"#Side_effects\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">Side effects</span></a></li>\n<li class=\"toclevel-1 tocsection-6\"><a href=\"#Legal_and_regulatory_issues\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">Legal and regulatory issues</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-7\"><a href=\"#Protandim_voluntary_recall\"><span class=\"tocnumber\">5.1</span> <span class=\"toctext\">Protandim voluntary recall</span></a></li>\n<li class=\"toclevel-2 tocsection-8\"><a href=\"#FDA_Warning_for_illegal_marketing_of_Protandim\"><span class=\"tocnumber\">5.2</span> <span class=\"toctext\">FDA Warning for illegal marketing of Protandim</span></a></li>\n<li class=\"toclevel-2 tocsection-9\"><a href=\"#Other\"><span class=\"tocnumber\">5.3</span> <span class=\"toctext\">Other</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-10\"><a href=\"#Promotional_sponsorship\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">Promotional sponsorship</span></a></li>\n<li class=\"toclevel-1 tocsection-11\"><a href=\"#See_also\"><span class=\"tocnumber\">7</span> <span class=\"toctext\">See also</span></a></li>\n<li class=\"toclevel-1 tocsection-12\"><a href=\"#References\"><span class=\"tocnumber\">8</span> <span class=\"toctext\">References</span></a></li>\n<li class=\"toclevel-1 tocsection-13\"><a href=\"#External_links\"><span class=\"tocnumber\">9</span> <span class=\"toctext\">External links</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"History\">History</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Protandim&amp;action=edit&amp;section=1\" title=\"Edit section: History\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>In 2003, Lifeline Therapeutics, a privately held Denver-based <a href=\"/wiki/Nutraceutical\" title=\"Nutraceutical\">nutraceutical</a> licensing and marketing company, entered into an agreement with Massachusetts biotechnology company CereMedix for the rights to market CMX-1152, an experimental <a href=\"/wiki/Peptide\" title=\"Peptide\">peptide</a>-based <a href=\"/wiki/Chemical_compound\" title=\"Chemical compound\">compound</a>, under the brand name \"Protandim\" (also sometimes referred to at that time as \"Rholen,\" \"Rejuven8r\" and \"ependymin\").<sup id=\"cite_ref-NutraceuticalsWorld_7-0\" class=\"reference\"><a href=\"#cite_note-NutraceuticalsWorld-7\">&#91;7&#93;</a></sup><sup id=\"cite_ref-BetterhumansPR_8-0\" class=\"reference\"><a href=\"#cite_note-BetterhumansPR-8\">&#91;8&#93;</a></sup><sup id=\"cite_ref-McCook_9-0\" class=\"reference\"><a href=\"#cite_note-McCook-9\">&#91;9&#93;</a></sup><sup id=\"cite_ref-PR101603_10-0\" class=\"reference\"><a href=\"#cite_note-PR101603-10\">&#91;10&#93;</a></sup><sup id=\"cite_ref-Betterhumans_11-0\" class=\"reference\"><a href=\"#cite_note-Betterhumans-11\">&#91;11&#93;</a></sup><sup id=\"cite_ref-Scotsman_12-0\" class=\"reference\"><a href=\"#cite_note-Scotsman-12\">&#91;12&#93;</a></sup><sup id=\"cite_ref-DenverPost_13-0\" class=\"reference\"><a href=\"#cite_note-DenverPost-13\">&#91;13&#93;</a></sup> CereMedix was a ten percent owner of Lifeline and members of the CereMedix management board served on Lifeline\u2019s board of directors. CMX-1152 was claimed to upregulate the production of the endogenous antioxidant enzymes <a href=\"/wiki/Superoxide_dismutase\" title=\"Superoxide dismutase\">superoxide dismutase</a>, <a href=\"/wiki/Catalase\" title=\"Catalase\">catalase</a>, and <a href=\"/wiki/Glutathione_peroxidase\" title=\"Glutathione peroxidase\">glutathione peroxidase</a>, and to offset the ageing process.<sup id=\"cite_ref-Scotsman_12-1\" class=\"reference\"><a href=\"#cite_note-Scotsman-12\">&#91;12&#93;</a></sup>\n</p><p>CMX-1152 was due to be marketed as an <a href=\"/wiki/Over_the_counter\" class=\"mw-redirect\" title=\"Over the counter\">over the counter</a> <a href=\"/wiki/Anti-aging\" class=\"mw-redirect\" title=\"Anti-aging\">anti-aging</a> pill in June 2004 after completing human clinical trials. However, plans to market the CMX-1152 version of Protandim fell through and in April 2004 Lifeline Therapeutics announced that it would instead be marketing a different (non-peptide) <a href=\"/wiki/Dietary_supplement\" title=\"Dietary supplement\">dietary supplement</a> under the name \u201cProtandim CF\u201d (to distinguish it from the peptide version initially developed by Cermedix). The new version of Protandim, a combination of 5 common <a href=\"/wiki/Herbal\" title=\"Herbal\">herbal</a> ingredients including <a href=\"/wiki/Turmeric\" title=\"Turmeric\">turmeric</a> and <a href=\"/wiki/Green_tea\" title=\"Green tea\">green tea</a> was invented following \u201cmonths of extensive research and development\u201d by Lifeline employees Paul Myhill and William Driscoll (a former oil company executive), who together hold the patent on the product,<sup id=\"cite_ref-Patent1_1-1\" class=\"reference\"><a href=\"#cite_note-Patent1-1\">&#91;1&#93;</a></sup> and it was  launched in February 2005. Myhill and Driscoll resigned from the company later that year.<sup id=\"cite_ref-DenverPost_13-1\" class=\"reference\"><a href=\"#cite_note-DenverPost-13\">&#91;13&#93;</a></sup><sup id=\"cite_ref-Footnoted_14-0\" class=\"reference\"><a href=\"#cite_note-Footnoted-14\">&#91;14&#93;</a></sup><sup id=\"cite_ref-DBJ_15-0\" class=\"reference\"><a href=\"#cite_note-DBJ-15\">&#91;15&#93;</a></sup><sup id=\"cite_ref-Myhill8K_16-0\" class=\"reference\"><a href=\"#cite_note-Myhill8K-16\">&#91;16&#93;</a></sup>\n</p><p>Like CMX-1152, the herbal mixture known as Protandim that supplanted it was marketed by Lifeline as an \"anti-aging\" supplement that increases the body\u2019s antioxidant defenses by upregulating superoxide dismutase, catalase, and glutathione peroxidase. According to the company, the product was initially sold through retail channels such as <a href=\"/wiki/GNC_(store)\" title=\"GNC (store)\">GNC</a>;<sup id=\"cite_ref-GNC_17-0\" class=\"reference\"><a href=\"#cite_note-GNC-17\">&#91;17&#93;</a></sup> however, in 2009, after several consecutive years of multimillion-dollar losses, the company,  which by then was doing business under the name LifeVantage, stopped marketing it through retailers and switched to multi-level marketing, selling it instead through a network of commissioned independent distributors. According to LifeVantage, the move from retail to multi-level marketing was prompted by the January 2008 hiring of David W. Brown, (formerly CEO and president of <a href=\"/wiki/Metabolife\" title=\"Metabolife\">Metabolife</a>) as the company's CEO and president.<sup id=\"cite_ref-ReutersBrown_18-0\" class=\"reference\"><a href=\"#cite_note-ReutersBrown-18\">&#91;18&#93;</a></sup><sup id=\"cite_ref-LFVNstory_19-0\" class=\"reference\"><a href=\"#cite_note-LFVNstory-19\">&#91;19&#93;</a></sup>\n</p><p>Beginning in 2005, Protandim  was produced under a manufacturing agreement with <a href=\"/wiki/Chemins\" title=\"Chemins\">The Chemins Company</a> of Colorado Springs, Colorado.<sup id=\"cite_ref-LIFEVANTAGE-CORP-Jan-2006-10KSB/A_20-0\" class=\"reference\"><a href=\"#cite_note-LIFEVANTAGE-CORP-Jan-2006-10KSB/A-20\">&#91;20&#93;</a></sup> In July 2008, LifeVantage entered into a new manufacturing agreement with Cornerstone Research &amp; Development to produce Protandim, and with Wasatch Product Development to produce a Protandim-based skin cream (<i>TrueScience</i>).<sup id=\"cite_ref-LIFEVANTAGE-CORP-Sep-2011-10-K_21-0\" class=\"reference\"><a href=\"#cite_note-LIFEVANTAGE-CORP-Sep-2011-10-K-21\">&#91;21&#93;</a></sup>\n</p><p>In 2006, biochemist <a href=\"/wiki/Joe_M._McCord\" title=\"Joe M. McCord\">Joe M. McCord</a> joined the LifeVantage board of directors as the company\u2019s Director of Science.<sup id=\"cite_ref-22\" class=\"reference\"><a href=\"#cite_note-22\">&#91;22&#93;</a></sup> McCord, who is listed by the SEC as a LifeVantage <a href=\"/wiki/Insider_trading\" title=\"Insider trading\">insider shareholder</a>,<sup id=\"cite_ref-secwatch.com_23-0\" class=\"reference\"><a href=\"#cite_note-secwatch.com-23\">&#91;23&#93;</a></sup> served as a spokesperson for Protandim and was responsible for distributor training and product research.<sup id=\"cite_ref-secwatch.com_23-1\" class=\"reference\"><a href=\"#cite_note-secwatch.com-23\">&#91;23&#93;</a></sup> Under the terms of his 2011 employment agreement, McCord received $529,994 in direct compensation as well as a 50-cent commission on every bottle of Protandim sold.<sup id=\"cite_ref-10K2011_24-0\" class=\"reference\"><a href=\"#cite_note-10K2011-24\">&#91;24&#93;</a></sup><sup id=\"cite_ref-McCordcontract_25-0\" class=\"reference\"><a href=\"#cite_note-McCordcontract-25\">&#91;25&#93;</a></sup> McCord served as LifeVantage\u2019s Chief Scientific Officer from June 2011 until September 2012, and then became a member of its science advisory board. LifeVantage announced McCord\u2019s retirement in June 2013.<sup id=\"cite_ref-retire1_26-0\" class=\"reference\"><a href=\"#cite_note-retire1-26\">&#91;26&#93;</a></sup><sup id=\"cite_ref-8Kretire2_27-0\" class=\"reference\"><a href=\"#cite_note-8Kretire2-27\">&#91;27&#93;</a></sup> Under the terms of the separation agreement, McCord was to receive a payment of $1.7 million from the company.<sup id=\"cite_ref-8Kretire2_27-1\" class=\"reference\"><a href=\"#cite_note-8Kretire2-27\">&#91;27&#93;</a></sup>\n</p><p>In January 2014, McCord was replaced by Shawn Talbott (developer of <a href=\"/wiki/CortiSlim\" title=\"CortiSlim\">CortiSlim</a>),<sup id=\"cite_ref-TalbottFTC_28-0\" class=\"reference\"><a href=\"#cite_note-TalbottFTC-28\">&#91;28&#93;</a></sup> who served as the company's Chief Science Officer<sup id=\"cite_ref-Talbott_29-0\" class=\"reference\"><a href=\"#cite_note-Talbott-29\">&#91;29&#93;</a></sup> until being relieved of his duties in June 2015<sup id=\"cite_ref-TalbottBlog_30-0\" class=\"reference\"><a href=\"#cite_note-TalbottBlog-30\">&#91;30&#93;</a></sup> and replaced in August 2015 by Natalie Chevreau, who was hired as the company's Senior VP of Research and Development and is credited with the invention of the company's TruScience skin care product.<sup id=\"cite_ref-ChevreauPatent_31-0\" class=\"reference\"><a href=\"#cite_note-ChevreauPatent-31\">&#91;31&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Product_invention\">Product invention</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Protandim&amp;action=edit&amp;section=2\" title=\"Edit section: Product invention\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>As recently as July 21, 2011, LifeVantage credited McCord as the creator of Protandim on its website.<sup id=\"cite_ref-InventControversy2_32-0\" class=\"reference\"><a href=\"#cite_note-InventControversy2-32\">&#91;32&#93;</a></sup> At a 2011 conference for LifeVantage distributors, McCord stated, \"I was presented with a list of 41 potential ingredients for a product they wanted to call Protandim, and I went through the list and penciled out, rapidly, about 36 of those ingredients,\" leaving the 5 ingredients in the current formulation of Protandim.<sup id=\"cite_ref-InventControversy3_33-0\" class=\"reference\"><a href=\"#cite_note-InventControversy3-33\">&#91;33&#93;</a></sup> In March 2009, former LifeLine Therapeutics executive, Paul Myhill stated, \"We initially decided to hide that fact [that Myhill derived the core composition for Protandim] for marketing purposes and instead rely on the impeccable background of Dr. McCord.\" <sup id=\"cite_ref-InventControversy1_34-0\" class=\"reference\"><a href=\"#cite_note-InventControversy1-34\">&#91;34&#93;</a></sup> In April, 2005, Myhill produced a signed letter from McCord in which McCord stated, \"I do not honestly feel that I have made contributions to the intellectual property, up to this point, that would qualify me as an inventor...I must congratulate you and Paul for having framed the concept of Protandim so close to its final embodiment, prior to the beginnings of our association.\"<sup id=\"cite_ref-InventControversy4_35-0\" class=\"reference\"><a href=\"#cite_note-InventControversy4-35\">&#91;35&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Composition\">Composition</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Protandim&amp;action=edit&amp;section=3\" title=\"Edit section: Composition\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Protandim consists mainly of a blend of 5 herbal ingredients (amounts per caplet listed in parentheses):<sup id=\"cite_ref-study2_36-0\" class=\"reference\"><a href=\"#cite_note-study2-36\">&#91;36&#93;</a></sup>\n</p>\n<ul><li><a href=\"/wiki/Silybum_marianum\" title=\"Silybum marianum\">Milk thistle</a> (<i>Silybum marianum</i>) extract (225&#160;mg)</li>\n<li><a href=\"/wiki/Bacopa_monnieri\" title=\"Bacopa monnieri\">Bacopa</a> (<i>Bacopa monnieri</i>) extract (150&#160;mg)</li>\n<li><a href=\"/wiki/Withania_somnifera\" title=\"Withania somnifera\">Ashwagandha</a> (<i>Withania somnifera</i>) root (150&#160;mg)</li>\n<li><a href=\"/wiki/Green_tea\" title=\"Green tea\">Green tea</a> (<i>Camellia sinensis</i>) extract (75&#160;mg)</li>\n<li><a href=\"/wiki/Turmeric\" title=\"Turmeric\">Turmeric</a> (<i>Curcuma longa</i>) extract (75&#160;mg)</li></ul>\n<h2><span class=\"mw-headline\" id=\"Effectiveness\">Effectiveness</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Protandim&amp;action=edit&amp;section=4\" title=\"Edit section: Effectiveness\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Claims that Protadim can prevent or treat <a href=\"/wiki/Cancer\" title=\"Cancer\">cancer</a> are unproven.<sup id=\"cite_ref-fda2017_37-0\" class=\"reference\"><a href=\"#cite_note-fda2017-37\">&#91;37&#93;</a></sup> Research into use as a treatment for <a href=\"/wiki/Amyotrophic_lateral_sclerosis\" title=\"Amyotrophic lateral sclerosis\">amyotrophic lateral sclerosis</a> is of poor quality, casting doubt on its usefulness for drawing any conclusions about efficacy.<sup id=\"cite_ref-38\" class=\"reference\"><a href=\"#cite_note-38\">&#91;38&#93;</a></sup>\n</p><p>In 2011, <a href=\"/wiki/Harriet_A._Hall\" class=\"mw-redirect\" title=\"Harriet A. Hall\">Harriet A. Hall</a> wrote for <i><a href=\"/wiki/Science-Based_Medicine_(website)\" class=\"mw-redirect\" title=\"Science-Based Medicine (website)\">Science-Based Medicine</a></i> that, \"We simply don\u2019t know enough at this point to recommend Protandim for treatment or prevention of any disease, for anti-aging, for making people feel healthier or more energetic, or for anything else.\"<sup id=\"cite_ref-39\" class=\"reference\"><a href=\"#cite_note-39\">&#91;39&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Side_effects\">Side effects</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Protandim&amp;action=edit&amp;section=5\" title=\"Edit section: Side effects\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>According to the manufacturer, Protandim can cause allergic responses, gastrointestinal disturbances (stomach ache, diarrhea, vomiting), headache, and rash of the hands and feet.<sup id=\"cite_ref-40\" class=\"reference\"><a href=\"#cite_note-40\">&#91;40&#93;</a></sup><sup id=\"cite_ref-SBM_120517_41-0\" class=\"reference\"><a href=\"#cite_note-SBM_120517-41\">&#91;41&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Legal_and_regulatory_issues\">Legal and regulatory issues</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Protandim&amp;action=edit&amp;section=6\" title=\"Edit section: Legal and regulatory issues\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<h3><span class=\"mw-headline\" id=\"Protandim_voluntary_recall\">Protandim voluntary recall</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Protandim&amp;action=edit&amp;section=7\" title=\"Edit section: Protandim voluntary recall\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>In December 2012, LifeVantage issued a voluntary recall of select lots (10 lots in total comprising 247,896 bottles) of Protandim due to potential health risks arising from the possible inclusion of small metal fragments in the final product.<sup id=\"cite_ref-42\" class=\"reference\"><a href=\"#cite_note-42\">&#91;42&#93;</a></sup><sup id=\"cite_ref-43\" class=\"reference\"><a href=\"#cite_note-43\">&#91;43&#93;</a></sup>  In February 2013, the company announced that it was extending the recall to include additional lots of the product, estimating the total cost of the recall at $5.9 million.<sup id=\"cite_ref-LIFEVANTAGE-CORP-Feb-2013-8-K_44-0\" class=\"reference\"><a href=\"#cite_note-LIFEVANTAGE-CORP-Feb-2013-8-K-44\">&#91;44&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"FDA_Warning_for_illegal_marketing_of_Protandim\">FDA Warning for illegal marketing of Protandim</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Protandim&amp;action=edit&amp;section=8\" title=\"Edit section: FDA Warning for illegal marketing of Protandim\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>On April 17, 2017, LifeVantage was issued a <a href=\"/wiki/FDA_warning_letter\" title=\"FDA warning letter\">warning letter</a> by the U.S. Food and Drug Administration (FDA) regarding illegal advertising claims on the company\u2019s websites suggesting that Protandim can play a role in helping to cure various ailments, including cancer and diabetes. The claims were deemed to be in violation of Section 201(g)(1)(B) of the <a href=\"/wiki/Federal_Food,_Drug,_and_Cosmetic_Act\" title=\"Federal Food, Drug, and Cosmetic Act\">Federal Food, Drug, and Cosmetic Act</a> (the Act) [21 U.S.C. \u00a7 321(g)(1)(B)].<sup id=\"cite_ref-SLT_042617_4-1\" class=\"reference\"><a href=\"#cite_note-SLT_042617-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-SBN_5-1\" class=\"reference\"><a href=\"#cite_note-SBN-5\">&#91;5&#93;</a></sup><sup id=\"cite_ref-fda0417_6-1\" class=\"reference\"><a href=\"#cite_note-fda0417-6\">&#91;6&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Other\">Other</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Protandim&amp;action=edit&amp;section=9\" title=\"Edit section: Other\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>In 2009, LifeVantage was sued by Utah-based Zrii LLC, a marketer of nutritional fruit drinks endorsed by <a href=\"/wiki/Deepak_Chopra\" title=\"Deepak Chopra\">Deepak Chopra</a>, based on allegations that LifeVantage had conspired with former Zrii executives to \u201cruin the company\u201d and take it over \u201con the cheap\u201d following a \u201cmass exodus\u201d. The case was closed in December 2009 following LifeVantage\u2019s settlement payment of $400,000 to Zrii.<sup id=\"cite_ref-Zrii_45-0\" class=\"reference\"><a href=\"#cite_note-Zrii-45\">&#91;45&#93;</a></sup>\n</p><p>On October 14, 2011, Burke Hedges, a former LifeVantage distributor (hired for his background as a speaker and trainer) filed a lawsuit with the Utah District Court against LifeVantage and its executives, seeking $3 million in punitive damages over allegations of wrongful termination and tortious interference.<sup id=\"cite_ref-Hedges_46-0\" class=\"reference\"><a href=\"#cite_note-Hedges-46\">&#91;46&#93;</a></sup>\n</p><p>In September 2016, a class action lawsuit was filed against LifeVantage in Utah alleging that the company and its executive Darren Jensen and Mark Jaggi made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects.  Specifically, the case alleged that the defendants made false and/or misleading statements and/or failed to disclose that: (i) LifeVantage lacked effective internal financial controls; (ii) as a result, the Company had improperly accounted for sales in certain international markets, along with associated revenue and income tax accruals; and (iii) as a result of the foregoing, LifeVantage's public statements were materially false and misleading at all relevant times.<sup id=\"cite_ref-Rosen091616_47-0\" class=\"reference\"><a href=\"#cite_note-Rosen091616-47\">&#91;47&#93;</a></sup><sup id=\"cite_ref-Zhang1_48-0\" class=\"reference\"><a href=\"#cite_note-Zhang1-48\">&#91;48&#93;</a></sup> The case was dismissed in June 2017.<sup id=\"cite_ref-LFVN102317_49-0\" class=\"reference\"><a href=\"#cite_note-LFVN102317-49\">&#91;49&#93;</a></sup><sup id=\"cite_ref-Zhang2_50-0\" class=\"reference\"><a href=\"#cite_note-Zhang2-50\">&#91;50&#93;</a></sup>\n</p><p>In January 2018, a class action lawsuit was filed against LifeVantage in Connecticut alleging that the company and its Chief Executive Officer Darren Jensen, Chief Sales Officer Justin Rose, and Chief Marketing Officer Ryan Goodwin were operating an illegal <a href=\"/wiki/Pyramid_scheme\" title=\"Pyramid scheme\">pyramid scheme</a> in violation of the <a href=\"/wiki/RICO_Act\" class=\"mw-redirect\" title=\"RICO Act\">RICO Act</a>, federal securities laws, and the Connecticut Unfair Trade Practices Act.<sup id=\"cite_ref-BW042718_51-0\" class=\"reference\"><a href=\"#cite_note-BW042718-51\">&#91;51&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Promotional_sponsorship\">Promotional sponsorship</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Protandim&amp;action=edit&amp;section=10\" title=\"Edit section: Promotional sponsorship\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p><a href=\"/wiki/Major_League_Soccer\" title=\"Major League Soccer\">Major League Soccer</a> team <a href=\"/wiki/Real_Salt_Lake\" title=\"Real Salt Lake\">Real Salt Lake</a> announced on October 29, 2013 that it had partnered with LifeVantage for a long-term, multimillion-dollar jersey-front sponsorship. The partnership was set to formally go into effect on January 1, 2014, with the LifeVantage logo appearing on the Real Salt Lake jersey starting in the next season.<sup id=\"cite_ref-RSL042717_52-0\" class=\"reference\"><a href=\"#cite_note-RSL042717-52\">&#91;52&#93;</a></sup> In July 2015, Real Salt Lake owner Dell Loy Hansen was reported by the U.S. <a href=\"/wiki/Securities_and_Exchange_Commission\" class=\"mw-redirect\" title=\"Securities and Exchange Commission\">Securities and Exchange Commission</a> to have bought a 5.1 percent ownership stake in LifeVantage.<sup id=\"cite_ref-SBN_5-2\" class=\"reference\"><a href=\"#cite_note-SBN-5\">&#91;5&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"See_also\">See also</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Protandim&amp;action=edit&amp;section=11\" title=\"Edit section: See also\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a href=\"/wiki/List_of_unproven_and_disproven_cancer_treatments\" title=\"List of unproven and disproven cancer treatments\">List of unproven and disproven cancer treatments</a></li>\n<li><a href=\"/wiki/Quackery\" title=\"Quackery\">Quackery</a></li></ul>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Protandim&amp;action=edit&amp;section=12\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist\" style=\"list-style-type: decimal;\">\n<div class=\"mw-references-wrap mw-references-columns\"><ol class=\"references\">\n<li id=\"cite_note-Patent1-1\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Patent1_1-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Patent1_1-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><span class=\"citation patent\" id=\"CITEREFMyhillDriscoll2007\"><a rel=\"nofollow\" class=\"external text\" href=\"https://worldwide.espacenet.com/textdoc?DB=EPODOC&amp;IDX=US7241461\">US 7241461</a>,&#32;Myhill, Paul R.&#32;&amp;&#32;William J. Driscoll,&#32;\"Composition for alleviating inflammation and oxidative stress in a mammal.\",&#32;issued 10 July 2007</span><span class=\"Z3988\" title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&amp;rft.number=7241461&amp;rft.cc=US&amp;rft.title=Composition+for+alleviating+inflammation+and+oxidative+stress+in+a+mammal.&amp;rft.inventor=Myhill&amp;rft.date=10 July 2007\"><span style=\"display: none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-LifeVantage-2\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-LifeVantage_2-0\">^</a></b></span> <span class=\"reference-text\">LifeVantage Corporation<cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.lifevantage.com/faqs/\">\"FAQs - LifeVantage\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">4 July</span> 2014</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=FAQs+-+LifeVantage&amp;rft_id=http%3A%2F%2Fwww.lifevantage.com%2Ffaqs%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-sbm2017-3\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-sbm2017_3-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a href=\"/wiki/Harriet_A._Hall\" class=\"mw-redirect\" title=\"Harriet A. Hall\">Hall H</a> (9 May 2017). <a rel=\"nofollow\" class=\"external text\" href=\"https://sciencebasedmedicine.org/protandim-update-new-studies-and-an-fda-warning-letter/\">\"Protandim Update: New Studies and an FDA Warning Letter\"</a>. Science-Based Medicine.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Protandim+Update%3A+New+Studies+and+an+FDA+Warning+Letter&amp;rft.pub=Science-Based+Medicine&amp;rft.date=2017-05-09&amp;rft.au=Hall+H&amp;rft_id=https%3A%2F%2Fsciencebasedmedicine.org%2Fprotandim-update-new-studies-and-an-fda-warning-letter%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-SLT_042617-4\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-SLT_042617_4-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-SLT_042617_4-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation news\">Kamrani, Christopher (April 26, 2017). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.sltrib.com/home/5221187-155/real-salt-lake-rsl-jersey-sponsor\">\"Real Salt Lake: RSL jersey sponsor LifeVantage in hot water with FDA over supplement's treatment claims\"</a>. <a href=\"/wiki/Salt_Lake_Tribune\" class=\"mw-redirect\" title=\"Salt Lake Tribune\">Salt Lake Tribune</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">April 26,</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Real+Salt+Lake%3A+RSL+jersey+sponsor+LifeVantage+in+hot+water+with+FDA+over+supplement%E2%80%99s+treatment+claims&amp;rft.date=2017-04-26&amp;rft.aulast=Kamrani&amp;rft.aufirst=Christopher&amp;rft_id=http%3A%2F%2Fwww.sltrib.com%2Fhome%2F5221187-155%2Freal-salt-lake-rsl-jersey-sponsor&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-SBN-5\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-SBN_5-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-SBN_5-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-SBN_5-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation news\">Montgomery, Matt (April 26, 2017). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.rslsoapbox.com/2017/4/26/15436756/rsl-kit-sponsor-lifevantage-cancer-treatment-claims-fda-warning\">\"FDA warns RSL kit sponsor LifeVantage over cancer treatment claims\"</a>. <a href=\"/wiki/SB_Nation\" title=\"SB Nation\">SB Nation</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">April 27,</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=FDA+warns+RSL+kit+sponsor+LifeVantage+over+cancer+treatment+claims&amp;rft.date=2017-04-26&amp;rft.aulast=Montgomery&amp;rft.aufirst=Matt&amp;rft_id=http%3A%2F%2Fwww.rslsoapbox.com%2F2017%2F4%2F26%2F15436756%2Frsl-kit-sponsor-lifevantage-cancer-treatment-claims-fda-warning&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-fda0417-6\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-fda0417_6-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-fda0417_6-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2017/ucm554234.htm\">\"2017 - Lifevantage Corp 4/17/17\"</a>. <i>www.fda.gov</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2017-04-25</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.fda.gov&amp;rft.atitle=2017+-+Lifevantage+Corp+4%2F17%2F17&amp;rft_id=https%3A%2F%2Fwww.fda.gov%2FICECI%2FEnforcementActions%2FWarningLetters%2F2017%2Fucm554234.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-NutraceuticalsWorld-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-NutraceuticalsWorld_7-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.highbeam.com/doc/1G1-112356866.html\">\"Lifeline Nutraceuticals, CereMedix sign agreement\"</a>. <i>Nutraceuticals World</i>. December 1, 2003<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2012-08-19</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nutraceuticals+World&amp;rft.atitle=Lifeline+Nutraceuticals%2C+CereMedix+sign+agreement&amp;rft.date=2003-12-01&amp;rft_id=http%3A%2F%2Fwww.highbeam.com%2Fdoc%2F1G1-112356866.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-BetterhumansPR-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-BetterhumansPR_8-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.prweb.com/releases/2004/12/prweb183718.htm\">\"The Uncertain Antiaging Pill (press release)\"</a>. <i>Betterhumans</i>. December 1, 2004<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2012-08-19</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Betterhumans&amp;rft.atitle=The+Uncertain+Antiaging+Pill+%28press+release%29&amp;rft.date=2004-12-01&amp;rft_id=http%3A%2F%2Fwww.prweb.com%2Freleases%2F2004%2F12%2Fprweb183718.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-McCook-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-McCook_9-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Alison McCook (February 2006). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.the-scientist.com/article/display/23192/#ixzz1DA5Ng18E\">\"Your Money for Your Life\"</a>. <i>The Scientist</i>. <b>20</b> (3): 33.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Scientist&amp;rft.atitle=Your+Money+for+Your+Life&amp;rft.volume=20&amp;rft.issue=3&amp;rft.pages=33&amp;rft.date=2006-02&amp;rft.au=Alison+McCook&amp;rft_id=http%3A%2F%2Fwww.the-scientist.com%2Farticle%2Fdisplay%2F23192%2F%23ixzz1DA5Ng18E&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-PR101603-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-PR101603_10-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"https://archive.is/20130414193633/http://www.cryonics.org/immortalist/january04/lifeline.htm\">\"LifeLine Therapeutics press release\"</a>. October 16, 2003. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://www.cryonics.org/immortalist/january04/lifeline.htm\">the original</a> on April 14, 2013<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2012-08-19</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=LifeLine+Therapeutics+press+release&amp;rft.date=2003-10-16&amp;rft_id=http%3A%2F%2Fwww.cryonics.org%2Fimmortalist%2Fjanuary04%2Flifeline.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Betterhumans-11\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Betterhumans_11-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Bailey, Patrick. <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20041204092646/http://www.betterhumans.com/Features/Reports/report.aspx?articleID=2004-11-29-1\">\"The Uncertain Antiaging Pill\"</a>. <i>Betterhumans</i>. Archived from the original on December 4, 2004<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2004-11-29</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Betterhumans&amp;rft.atitle=The+Uncertain+Antiaging+Pill&amp;rft.aulast=Bailey&amp;rft.aufirst=Patrick&amp;rft_id=http%3A%2F%2Fwww.betterhumans.com%2FFeatures%2FReports%2Freport.aspx%3FarticleID%3D2004-11-29-1&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><span class=\"citation-comment\" style=\"display:none; color:#33aa33; margin-left:0.3em\">CS1 maint: Unfit url (<a href=\"/wiki/Category:CS1_maint:_Unfit_url\" title=\"Category:CS1 maint: Unfit url\">link</a>) </span></span>\n</li>\n<li id=\"cite_note-Scotsman-12\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Scotsman_12-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Scotsman_12-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.scotsman.com/news/scientist-returns-to-build-long-life-pill-plant-1-894387\">\"Scientist returns to build long-life pill plant\"</a>. <i><a href=\"/wiki/The_Scotsman\" title=\"The Scotsman\">The Scotsman</a></i>. November 17, 2003<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2012-08-20</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Scotsman&amp;rft.atitle=Scientist+returns+to+build+long-life+pill+plant&amp;rft.date=2003-11-17&amp;rft_id=http%3A%2F%2Fwww.scotsman.com%2Fnews%2Fscientist-returns-to-build-long-life-pill-plant-1-894387&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-DenverPost-13\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-DenverPost_13-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-DenverPost_13-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation news\">Austin, Marsha (December 8, 2003). <a rel=\"nofollow\" class=\"external text\" href=\"http://business.highbeam.com/3563/article-1G1-111038316/denver-businessmen-gamble-selling-fountain-youth-pill\">\"Denver Businessmen Gamble on Selling Fountain of Youth in Pill Form\"</a>. <i><a href=\"/wiki/Denver_Post\" class=\"mw-redirect\" title=\"Denver Post\">Denver Post</a></i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2012-08-20</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Denver+Post&amp;rft.atitle=Denver+Businessmen+Gamble+on+Selling+Fountain+of+Youth+in+Pill+Form&amp;rft.date=2003-12-08&amp;rft.aulast=Austin&amp;rft.aufirst=Marsha&amp;rft_id=http%3A%2F%2Fbusiness.highbeam.com%2F3563%2Farticle-1G1-111038316%2Fdenver-businessmen-gamble-selling-fountain-youth-pill&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Footnoted-14\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Footnoted_14-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.footnoted.com/uncategorized/some-days-its-just-hard-to-believe/\">\"Some days it's just hard to believe\"</a>. <i>Footnoted</i>. November 17, 2005<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2012-08-19</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Footnoted&amp;rft.atitle=Some+days+it%27s+just+hard+to+believe&amp;rft.date=2005-11-17&amp;rft_id=http%3A%2F%2Fwww.footnoted.com%2Funcategorized%2Fsome-days-its-just-hard-to-believe%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-DBJ-15\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-DBJ_15-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.bizjournals.com/denver/stories/2005/07/04/daily12.html\">\"Lifeline Therapeutics CEO resigns\"</a>. <i><a href=\"/wiki/Denver_Business_Journal\" class=\"mw-redirect\" title=\"Denver Business Journal\">Denver Business Journal</a></i>. July 5, 2005<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2012-08-20</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Denver+Business+Journal&amp;rft.atitle=Lifeline+Therapeutics+CEO+resigns&amp;rft.date=2005-07-05&amp;rft_id=http%3A%2F%2Fwww.bizjournals.com%2Fdenver%2Fstories%2F2005%2F07%2F04%2Fdaily12.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Myhill8K-16\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Myhill8K_16-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.sec.gov/Archives/edgar/data/849146/000102189005000208/lifeline1111058kex991.htm\">\"Paul R. Myhill. RE: Resignation from the Board of Directors and Executive Committee of Lifeline Therapeutics, Inc (Form 8-K)\"</a>. <i><a href=\"/wiki/United_States_Securities_and_Exchange_Commission\" class=\"mw-redirect\" title=\"United States Securities and Exchange Commission\">United States Securities and Exchange Commission</a></i>. November 11, 2005<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2012-08-20</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=United+States+Securities+and+Exchange+Commission&amp;rft.atitle=Paul+R.+Myhill.+RE%3A+Resignation+from+the+Board+of+Directors+and+Executive+Committee+of+Lifeline+Therapeutics%2C+Inc+%28Form+8-K%29&amp;rft.date=2005-11-11&amp;rft_id=https%3A%2F%2Fwww.sec.gov%2FArchives%2Fedgar%2Fdata%2F849146%2F000102189005000208%2Flifeline1111058kex991.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-GNC-17\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-GNC_17-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.sec.gov/Archives/edgar/data/849146/000102189005000106/lifeline720058kex99.htm\">\"Protandim to be Available at General Nutrition Center (GNC) Stores\"</a>. <i>Lifeline Therapeutics press release</i>. July 20, 2005<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2012-08-19</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Lifeline+Therapeutics+press+release&amp;rft.atitle=Protandim+to+be+Available+at+General+Nutrition+Center+%28GNC%29+Stores&amp;rft.date=2005-07-20&amp;rft_id=https%3A%2F%2Fwww.sec.gov%2FArchives%2Fedgar%2Fdata%2F849146%2F000102189005000106%2Flifeline720058kex99.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-ReutersBrown-18\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-ReutersBrown_18-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.reuters.com/article/2008/01/14/idUS120817+14-Jan-2008+PRN20080114\">\"LifeVantage Corporation Appoints Industry Veteran David Brown as President &amp; CEO (LFVN press release)\"</a>. <i><a href=\"/wiki/Reuters\" title=\"Reuters\">Reuters</a></i>. January 14, 2008<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2012-08-24</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Reuters&amp;rft.atitle=LifeVantage+Corporation+Appoints+Industry+Veteran+David+Brown+as+President+%26+CEO+%28LFVN+press+release%29&amp;rft.date=2008-01-14&amp;rft_id=https%3A%2F%2Fwww.reuters.com%2Farticle%2F2008%2F01%2F14%2FidUS120817%2B14-Jan-2008%2BPRN20080114&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-LFVNstory-19\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-LFVNstory_19-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20111112065451/http://www.lifevantage.com/company/our-story/\">\"The LifeVantage Story\"</a>. LifeVantage, Inc. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://www.lifevantage.com/company/our-story/\">the original</a> on 2011-11-12<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2012-08-24</span></span>. <q>David Brown, President of LifeVantage Network, recognized Protandim's potential.</q></cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=The+LifeVantage+Story&amp;rft.pub=LifeVantage%2C+Inc&amp;rft_id=http%3A%2F%2Fwww.lifevantage.com%2Fcompany%2Four-story%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-LIFEVANTAGE-CORP-Jan-2006-10KSB/A-20\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-LIFEVANTAGE-CORP-Jan-2006-10KSB/A_20-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://edgar.secdatabase.com/135/102189006000015/filing-main.htm\">\"LIFEVANTAGE CORP, Form 10KSB/A, Filing Date Jan 26, 2006\"</a>. secdatabase.com<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">May 15,</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=LIFEVANTAGE+CORP%2C+Form+10KSB%2FA%2C+Filing+Date+Jan+26%2C+2006&amp;rft.pub=secdatabase.com&amp;rft_id=http%3A%2F%2Fedgar.secdatabase.com%2F135%2F102189006000015%2Ffiling-main.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-LIFEVANTAGE-CORP-Sep-2011-10-K-21\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-LIFEVANTAGE-CORP-Sep-2011-10-K_21-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://pdf.secdatabase.com/988/0001193125-11-258536.pdf\">\"LIFEVANTAGE CORP, Form 10-K, Annual Report, Filing Date Sep 28, 2011\"</a> <span style=\"font-size:85%;\">(PDF)</span>. secdatabase.com<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">May 15,</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=LIFEVANTAGE+CORP%2C+Form+10-K%2C+Annual+Report%2C+Filing+Date+Sep+28%2C+2011&amp;rft.pub=secdatabase.com&amp;rft_id=http%3A%2F%2Fpdf.secdatabase.com%2F988%2F0001193125-11-258536.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-22\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-22\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"http://www.allbusiness.com/company-activities-management/board-management/5376294-1.html\">http://www.allbusiness.com/company-activities-management/board-management/5376294-1.html</a><sup class=\"noprint Inline-Template\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citing_sources#What_information_to_include\" title=\"Wikipedia:Citing sources\"><span title=\"A complete citation is needed (July 2013)\">full citation needed</span></a></i>&#93;</sup></span>\n</li>\n<li id=\"cite_note-secwatch.com-23\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-secwatch.com_23-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-secwatch.com_23-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20110304012432/http://secwatch.com/mccord-joe-m\">\"Archived copy\"</a>. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://secwatch.com/mccord-joe-m\">the original</a> on 2011-03-04<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2011-02-16</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Archived+copy&amp;rft_id=http%3A%2F%2Fsecwatch.com%2Fmccord-joe-m&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><sup class=\"noprint Inline-Template\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citing_sources#What_information_to_include\" title=\"Wikipedia:Citing sources\"><span title=\"A complete citation is needed (July 2013)\">full citation needed</span></a></i>&#93;</sup></span>\n</li>\n<li id=\"cite_note-10K2011-24\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-10K2011_24-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.sec.gov/Archives/edgar/data/849146/000119312511258536/d225491d10k.htm\">\"LifeVantage Corp 10-K 2011\"</a>. sec.edgar-online.com<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">September 5,</span> 2015</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=LifeVantage+Corp+10-K+2011&amp;rft.pub=sec.edgar-online.com&amp;rft_id=https%3A%2F%2Fwww.sec.gov%2FArchives%2Fedgar%2Fdata%2F849146%2F000119312511258536%2Fd225491d10k.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-McCordcontract-25\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-McCordcontract_25-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.sec.gov/Archives/edgar/data/849146/000119312511258536/d225491dex1031.htm\">\"Employment agreement with Dr. Joe McCord\"</a>. <a href=\"/wiki/U.S._Securities_and_Exchange_Commission\" title=\"U.S. Securities and Exchange Commission\">U.S. Securities and Exchange Commission</a>. April 1, 2011<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2014-09-21</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Employment+agreement+with+Dr.+Joe+McCord&amp;rft.pub=U.S.+Securities+and+Exchange+Commission&amp;rft.date=2011-04-01&amp;rft_id=https%3A%2F%2Fwww.sec.gov%2FArchives%2Fedgar%2Fdata%2F849146%2F000119312511258536%2Fd225491dex1031.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-retire1-26\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-retire1_26-0\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"http://globenewswire.com/news-release/2013/06/25/556132/10037495/en/Dr-Joe-McCord-LifeVantage-Corporation-s-First-Chief-Science-Officer-Retires-From-Company.html\">http://globenewswire.com/news-release/2013/06/25/556132/10037495/en/Dr-Joe-McCord-LifeVantage-Corporation-s-First-Chief-Science-Officer-Retires-From-Company.html</a><sup class=\"noprint Inline-Template\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citing_sources#What_information_to_include\" title=\"Wikipedia:Citing sources\"><span title=\"A complete citation is needed (July 2013)\">full citation needed</span></a></i>&#93;</sup></span>\n</li>\n<li id=\"cite_note-8Kretire2-27\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-8Kretire2_27-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-8Kretire2_27-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"http://biz.yahoo.com/e/130625/lfvn8-k.html\">\"Form 8-K for LifeVantage Corp\"</a>. <i>Yahoo.com</i>. June 25, 2013<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">10 November</span> 2013</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Yahoo.com&amp;rft.atitle=Form+8-K+for+LifeVantage+Corp&amp;rft.date=2013-06-25&amp;rft_id=http%3A%2F%2Fbiz.yahoo.com%2Fe%2F130625%2Flfvn8-k.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-TalbottFTC-28\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-TalbottFTC_28-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.ftc.gov/news-events/press-releases/2005/09/three-cortislim-defendants-give-45-million-cash-and-other-assets\">\"Three Cortislim Defendants to Give up $4.5 Million in Cash and Other Assets\"</a>. <a href=\"/wiki/Federal_Trade_Commission\" title=\"Federal Trade Commission\">Federal Trade Commission</a>. September 21, 2005<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">July 14,</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Three+Cortislim+Defendants+to+Give+up+%244.5+Million+in+Cash+and+Other+Assets&amp;rft.pub=Federal+Trade+Commission&amp;rft.date=2005-09-21&amp;rft_id=https%3A%2F%2Fwww.ftc.gov%2Fnews-events%2Fpress-releases%2F2005%2F09%2Fthree-cortislim-defendants-give-45-million-cash-and-other-assets&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Talbott-29\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Talbott_29-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://globenewswire.com/news-release/2014/01/07/600765/10063209/en/LifeVantage-Corporation-Appoints-Shawn-Talbott-Ph-D-as-New-Global-Chief-Science-Officer.html\">\"LifeVantage Corporation Appoints Shawn Talbott Ph.D. as New Global Chief Science Officer\"</a>. LifeVantage, Inc. January 7, 2014<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">July 14,</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=LifeVantage+Corporation+Appoints+Shawn+Talbott+Ph.D.+as+New+Global+Chief+Science+Officer&amp;rft.pub=LifeVantage%2C+Inc.&amp;rft.date=2014-01-07&amp;rft_id=https%3A%2F%2Fglobenewswire.com%2Fnews-release%2F2014%2F01%2F07%2F600765%2F10063209%2Fen%2FLifeVantage-Corporation-Appoints-Shawn-Talbott-Ph-D-as-New-Global-Chief-Science-Officer.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-TalbottBlog-30\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-TalbottBlog_30-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Shawn M. Talbott (July 13, 2015). <a rel=\"nofollow\" class=\"external text\" href=\"https://bestfutureyou.com/2015/07/13/my-new-gig/\">\"My New Gig?\"</a>. <i>Shawn M. Talbott Personal Blog</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">July 14,</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Shawn+M.+Talbott+Personal+Blog&amp;rft.atitle=My+New+Gig%3F&amp;rft.date=2015-07-13&amp;rft.au=Shawn+M.+Talbott&amp;rft_id=https%3A%2F%2Fbestfutureyou.com%2F2015%2F07%2F13%2Fmy-new-gig%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-ChevreauPatent-31\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-ChevreauPatent_31-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.google.com/patents/WO2015164504A1?cl=en\">\"Patent WO 2015164504 A1: Topical compositions and methods for reducing oxidative stress\"</a>. October 29, 2015<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">July 14,</span> 2016</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Patent+WO+2015164504+A1%3A+Topical+compositions+and+methods+for+reducing+oxidative+stress&amp;rft.date=2015-10-29&amp;rft_id=http%3A%2F%2Fwww.google.com%2Fpatents%2FWO2015164504A1%3Fcl%3Den&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-InventControversy2-32\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-InventControversy2_32-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20110721233521/http://www.lifevantage.com/products-breakthrough.aspx\">\"Scientific Breakthrough. &#91;Filed 21 July 2011&#93;\"</a>. Archived from the original on 21 July 2011.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Scientific+Breakthrough.+%5BFiled+21+July+2011%5D&amp;rft_id=http%3A%2F%2Fwww.lifevantage.com%2Fproducts-breakthrough.aspx&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><span class=\"citation-comment\" style=\"display:none; color:#33aa33; margin-left:0.3em\">CS1 maint: BOT: original-url status unknown (<a href=\"/wiki/Category:CS1_maint:_BOT:_original-url_status_unknown\" title=\"Category:CS1 maint: BOT: original-url status unknown\">link</a>) </span></span>\n</li>\n<li id=\"cite_note-InventControversy3-33\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-InventControversy3_33-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://youtube.googleapis.com/v/C5vli73g_CA&amp;start=2303\">\"The History of Free Radical Biology, Dr. Joe McCord &#91;Filed 17 August 2011&#93;\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2012-08-13</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=The+History+of+Free+Radical+Biology%2C+Dr.+Joe+McCord+%5BFiled+17+August+2011%5D&amp;rft_id=http%3A%2F%2Fyoutube.googleapis.com%2Fv%2FC5vli73g_CA%26start%3D2303&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-InventControversy1-34\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-InventControversy1_34-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.blogtalkradio.com/lifevantage/blog/2009/03/09/inside-protandim-the-paul-myhill-interview\">\"Inside Protandim: The Paul Myhill Interview &#91;Filed 09 March 2009&#93;\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2012-08-13</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Inside+Protandim%3A+The+Paul+Myhill+Interview+%5BFiled+09+March+2009%5D&amp;rft_id=http%3A%2F%2Fwww.blogtalkradio.com%2Flifevantage%2Fblog%2F2009%2F03%2F09%2Finside-protandim-the-paul-myhill-interview&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-InventControversy4-35\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-InventControversy4_35-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://static.protandimscams.com/images/mccord-didnt-invent-protandim.jpg\">\"McCord Rejects Credit for Inventing Protandim &#91;Filed 29 March 2005&#93;\"</a>. Joe McCord<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2012-08-13</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=McCord+Rejects+Credit+for+Inventing+Protandim+%5BFiled+29+March+2005%5D&amp;rft.pub=Joe+McCord&amp;rft_id=http%3A%2F%2Fstatic.protandimscams.com%2Fimages%2Fmccord-didnt-invent-protandim.jpg&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-study2-36\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-study2_36-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Velmurugan, Kalpana; Alam, Jawed; McCord, Joe M.; Pugazhenthi, Subbiah (2009). \"Synergistic induction of heme oxygenase-1 by the components of the antioxidant supplement Protandim\". <i>Free Radical Biology and Medicine</i>. <b>46</b> (3): 430\u201340. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/j.freeradbiomed.2008.10.050\">10.1016/j.freeradbiomed.2008.10.050</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/19056485\">19056485</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Free+Radical+Biology+and+Medicine&amp;rft.atitle=Synergistic+induction+of+heme+oxygenase-1+by+the+components+of+the+antioxidant+supplement+Protandim&amp;rft.volume=46&amp;rft.issue=3&amp;rft.pages=430-40&amp;rft.date=2009&amp;rft_id=info%3Adoi%2F10.1016%2Fj.freeradbiomed.2008.10.050&amp;rft_id=info%3Apmid%2F19056485&amp;rft.aulast=Velmurugan&amp;rft.aufirst=Kalpana&amp;rft.au=Alam%2C+Jawed&amp;rft.au=McCord%2C+Joe+M.&amp;rft.au=Pugazhenthi%2C+Subbiah&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-fda2017-37\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-fda2017_37-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20180424192807/https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm554777.htm\">\"Illegal Cancer Treatments: FDA Warning - Fraudulent Claims of Diagnosis, Treatment, Prevention or Cure\"</a>. FDA. 25 April 2017. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm554777.htm\">the original</a> on 24 April 2018.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Illegal+Cancer+Treatments%3A+FDA+Warning+-+Fraudulent+Claims+of+Diagnosis%2C+Treatment%2C+Prevention+or+Cure&amp;rft.pub=FDA&amp;rft.date=2017-04-25&amp;rft_id=https%3A%2F%2Fwww.fda.gov%2FSafety%2FMedWatch%2FSafetyInformation%2FSafetyAlertsforHumanMedicalProducts%2Fucm554777.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-38\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-38\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">ALSUntangled Group (2015). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;tool=sumsearch.org/cite&amp;retmode=ref&amp;cmd=prlinks&amp;id=26414415\">\"ALSUntangled No. 31: Protandim\"</a>. <i>Amyotroph Lateral Scler Frontotemporal Degener</i> (Review). <b>17</b> (1-2): 154\u20136. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.3109/21678421.2015.1088707\">10.3109/21678421.2015.1088707</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/26414415\">26414415</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Amyotroph+Lateral+Scler+Frontotemporal+Degener&amp;rft.atitle=ALSUntangled+No.+31%3A+Protandim.&amp;rft.volume=17&amp;rft.issue=1-2&amp;rft.pages=154-6&amp;rft.date=2015&amp;rft_id=info%3Adoi%2F10.3109%2F21678421.2015.1088707&amp;rft_id=info%3Apmid%2F26414415&amp;rft.au=ALSUntangled+Group&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fentrez%2Feutils%2Felink.fcgi%3Fdbfrom%3Dpubmed%26tool%3Dsumsearch.org%2Fcite%26retmode%3Dref%26cmd%3Dprlinks%26id%3D26414415&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span> </span>\n</li>\n<li id=\"cite_note-39\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-39\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Hall, Harriet. <a rel=\"nofollow\" class=\"external text\" href=\"http://www.sciencebasedmedicine.org/index.php/pursued-by-protandim-proselytizers/\">\"Pursued by Protandim Proselytizers\"</a>. <a href=\"/wiki/Science-Based_Medicine_(website)\" class=\"mw-redirect\" title=\"Science-Based Medicine (website)\">Science-Based Medicine</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">12 November</span> 2011</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Pursued+by+Protandim+Proselytizers&amp;rft.pub=Science-Based+Medicine&amp;rft.aulast=Hall&amp;rft.aufirst=Harriet&amp;rft_id=http%3A%2F%2Fwww.sciencebasedmedicine.org%2Findex.php%2Fpursued-by-protandim-proselytizers%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-40\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-40\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.protandim.com/faqs\">\"FAQ\"</a>. protandim.com.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=FAQ&amp;rft.pub=protandim.com&amp;rft_id=http%3A%2F%2Fwww.protandim.com%2Ffaqs&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span><sup class=\"noprint Inline-Template noprint Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Independent_sources\" class=\"mw-redirect\" title=\"Wikipedia:Independent sources\"><span title=\"This claim needs a reference to a independent, third-party source. (September 2012)\">third-party source needed</span></a></i>&#93;</sup></span>\n</li>\n<li id=\"cite_note-SBM_120517-41\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-SBM_120517_41-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Hall, Harriet (December 5, 2017). <a rel=\"nofollow\" class=\"external text\" href=\"https://sciencebasedmedicine.org/i-was-wrong-about-protandim/\">\"I Was Wrong about Protandim\"</a>. <i><a href=\"/wiki/Science_Based_Medicine\" class=\"mw-redirect\" title=\"Science Based Medicine\">Science Based Medicine</a></i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">June 26,</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Science+Based+Medicine&amp;rft.atitle=I+Was+Wrong+about+Protandim&amp;rft.date=2017-12-05&amp;rft.aulast=Hall&amp;rft.aufirst=Harriet&amp;rft_id=https%3A%2F%2Fsciencebasedmedicine.org%2Fi-was-wrong-about-protandim%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-42\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-42\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation pressrelease\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.fda.gov/Safety/Recalls/ucm331258.htm\">\"LifeVantage Corporation Announces Voluntary Recall and Replacement of Select Lots of Protandim\u00ae Dietary Supplement Due to Potential Health Risk\"</a> (Press release). 5 December 2012<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">7 December</span> 2012</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=LifeVantage+Corporation+Announces+Voluntary+Recall+and+Replacement+of+Select+Lots+of+Protandim%C2%AE+Dietary+Supplement+Due+to+Potential+Health+Risk&amp;rft.date=2012-12-05&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2FSafety%2FRecalls%2Fucm331258.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-43\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-43\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?action=select&amp;recall_number=F-0876-2013&amp;w=01162013&amp;lang=eng\">\"Enforcement Report - Week of January 16, 2013\"</a>. <a href=\"/wiki/U.S._Food_and_Drug_Administration\" class=\"mw-redirect\" title=\"U.S. Food and Drug Administration\">U.S. Food and Drug Administration</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">10 August</span> 2013</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Enforcement+Report+-+Week+of+January+16%2C+2013&amp;rft.pub=U.S.+Food+and+Drug+Administration&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fscripts%2Fenforcement%2Fenforce_rpt-Product-Tabs.cfm%3Faction%3Dselect%26recall_number%3DF-0876-2013%26w%3D01162013%26lang%3Deng&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-LIFEVANTAGE-CORP-Feb-2013-8-K-44\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-LIFEVANTAGE-CORP-Feb-2013-8-K_44-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://edgar.secdatabase.com/2677/119312513053627/filing-main.htm\">\"LIFEVANTAGE CORP, Form 8-K, Current Report, Filing Date Feb 13, 2013\"</a>. secdatabase.com<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">May 15,</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=LIFEVANTAGE+CORP%2C+Form+8-K%2C+Current+Report%2C+Filing+Date+Feb+13%2C+2013&amp;rft.pub=secdatabase.com&amp;rft_id=http%3A%2F%2Fedgar.secdatabase.com%2F2677%2F119312513053627%2Ffiling-main.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Zrii-45\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Zrii_45-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Harvey, Tom (2009-12-23). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.daily-times.com/ci_14059464\">\"Supplement company Zrii settles suits against rebellious ex-managers: LifeVantage pays $400,000 in dispute stemming from failed takeover attempt\"</a>. Salt Lake Tribune<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">6 November</span> 2011</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Supplement+company+Zrii+settles+suits+against+rebellious+ex-managers%3A+LifeVantage+pays+%24400%2C000+in+dispute+stemming+from+failed+takeover+attempt&amp;rft.pub=Salt+Lake+Tribune&amp;rft.date=2009-12-23&amp;rft.aulast=Harvey&amp;rft.aufirst=Tom&amp;rft_id=http%3A%2F%2Fwww.daily-times.com%2Fci_14059464&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Hedges-46\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Hedges_46-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">\"Burke Hedges V. Lifevantage Corporation\". United States District Court for the District of Utah: Civil No. 110918424. October 14, 2011.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Burke+Hedges+V.+Lifevantage+Corporation&amp;rft.pub=United+States+District+Court+for+the+District+of+Utah%3A+Civil+No.+110918424&amp;rft.date=2011-10-14&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span> <span style=\"display:none;font-size:100%\" class=\"error citation-comment\">Missing or empty <code style=\"color:inherit; border:inherit; padding:inherit;\">&#124;url=</code> (<a href=\"/wiki/Help:CS1_errors#cite_web_url\" title=\"Help:CS1 errors\">help</a>)</span></span>\n</li>\n<li id=\"cite_note-Rosen091616-47\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Rosen091616_47-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Rosen Law Firm (September 16, 2016). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.rosenlegal.com/cases-952.html\">\"Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against LifeVantage Corporation \u2013 LFVN\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">April 27,</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Rosen+Law+Firm+Announces+Filing+of+Securities+Class+Action+Lawsuit+Against+LifeVantage+Corporation+%E2%80%93+LFVN&amp;rft.date=2016-09-16&amp;rft.au=Rosen+Law+Firm&amp;rft_id=https%3A%2F%2Fwww.rosenlegal.com%2Fcases-952.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Zhang1-48\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Zhang1_48-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://securities.stanford.edu/filings-documents/1059/LC00_02/2016915_f01c_16CV00965.pdf\">\"Zhang v LifeVantage et al: Case 2:16-cv-00965-BCW\"</a> <span style=\"font-size:85%;\">(PDF)</span>. September 15, 2018<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">April 27,</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Zhang+v+LifeVantage+et+al%3A+Case+2%3A16-cv-00965-BCW&amp;rft.date=2018-09-15&amp;rft_id=http%3A%2F%2Fsecurities.stanford.edu%2Ffilings-documents%2F1059%2FLC00_02%2F2016915_f01c_16CV00965.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-LFVN102317-49\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-LFVN102317_49-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://globenewswire.com/news-release/2017/10/23/1151587/0/en/LifeVantage-Announces-Dismissal-of-Class-Action-Lawsuit.html\">\"LifeVantage Announces Dismissal of Class Action Lawsuit\"</a>. Lifevantage. October 10, 2017<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">April 27,</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=LifeVantage+Announces+Dismissal+of+Class+Action+Lawsuit&amp;rft.pub=Lifevantage&amp;rft.date=2017-10-10&amp;rft_id=https%3A%2F%2Fglobenewswire.com%2Fnews-release%2F2017%2F10%2F23%2F1151587%2F0%2Fen%2FLifeVantage-Announces-Dismissal-of-Class-Action-Lawsuit.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Zhang2-50\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Zhang2_50-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://ecf.utd.uscourts.gov/cgi-bin/show_public_doc?216cv0965-51\">\"Zhang v Lifevantage et al: Memorandum decision and order granting defendants' motion to dismiss\"</a>. June 15, 2017<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">April 27,</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Zhang+v+Lifevantage+et+al%3A+Memorandum+decision+and+order+granting+defendants%E2%80%99+motion+to+dismiss.&amp;rft.date=2017-06-15&amp;rft_id=https%3A%2F%2Fecf.utd.uscourts.gov%2Fcgi-bin%2Fshow_public_doc%3F216cv0965-51&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-BW042718-51\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-BW042718_51-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.businesswire.com/news/home/20180219005625/en/Sommers-Schwartz-P.C.-Announces-Filing-Securities-Class\">\"Sommers Schwartz, P.C. Announces the Filing of a Securities Class Action Claims Against LifeVantage Corp. and Certain of its Executives\"</a>. <i>Business Wire</i>. February 19, 2018<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">April 27,</span> 2018</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Business+Wire&amp;rft.atitle=Sommers+Schwartz%2C+P.C.+Announces+the+Filing+of+a+Securities+Class+Action+Claims+Against+LifeVantage+Corp.+and+Certain+of+its+Executives&amp;rft.date=2018-02-19&amp;rft_id=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20180219005625%2Fen%2FSommers-Schwartz-P.C.-Announces-Filing-Securities-Class&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-RSL042717-52\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-RSL042717_52-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.rsl.com/post/2013/10/29/real-salt-lake-unveils-new-long-term-jersey-front-partnership-lifevantage\">\"Real Salt Lake unveils new long-term jersey-front partnership with LifeVantage\"</a>. RealSaltLake.com. October 29, 2013<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">April 27,</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Real+Salt+Lake+unveils+new+long-term+jersey-front+partnership+with+LifeVantage&amp;rft.date=2013-10-29&amp;rft_id=https%3A%2F%2Fwww.rsl.com%2Fpost%2F2013%2F10%2F29%2Freal-salt-lake-unveils-new-long-term-jersey-front-partnership-lifevantage&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AProtandim\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div></div>\n<h2><span class=\"mw-headline\" id=\"External_links\">External links</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Protandim&amp;action=edit&amp;section=13\" title=\"Edit section: External links\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.lifevantage.com\">LifeVantage Corporation</a>, the manufacturer of Protandim</li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.sciencebasedmedicine.org/index.php/pursued-by-protandim-proselytizers/\">Pursued by Protandim Proselytizers</a></li></ul>\n\n<!-- \nNewPP limit report\nParsed by mw2168\nCached time: 20180919001449\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.464 seconds\nReal time usage: 0.556 seconds\nPreprocessor visited node count: 2538/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 85393/2097152 bytes\nTemplate argument size: 3084/2097152 bytes\nHighest expansion depth: 12/40\nExpensive parser function count: 2/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 58886/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.237/10.000 seconds\nLua memory usage: 4.01 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  470.134      1 -total\n 87.05%  409.232      1 Template:Reflist\n 30.94%  145.441     30 Template:Cite_web\n 14.99%   70.458      4 Template:Fix\n 14.37%   67.573      3 Template:Full_citation_needed\n 13.21%   62.083     15 Template:Cite_news\n  9.45%   44.408      4 Template:Category_handler\n  6.04%   28.411      1 Template:Short_description\n  5.99%   28.164      1 Template:Third-party-inline\n  5.51%   25.902      1 Template:Pagetype\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:12155777-0!canonical and timestamp 20180919001448 and revision id 860195882\n -->\n</div>"},"langlinks":[{"lang":"ko","url":"https://ko.wikipedia.org/wiki/%ED%94%84%EB%A1%9C%ED%83%84%EB%94%A4","langname":"Korean","autonym":"\ud55c\uad6d\uc5b4","*":"\ud504\ub85c\ud0c4\ub524"},{"lang":"ja","url":"https://ja.wikipedia.org/wiki/%E3%83%97%E3%83%AD%E3%82%BF%E3%83%B3%E3%83%87%E3%82%A3%E3%83%A0","langname":"Japanese","autonym":"\u65e5\u672c\u8a9e","*":"\u30d7\u30ed\u30bf\u30f3\u30c7\u30a3\u30e0"}],"categories":[{"sortkey":"","hidden":"","*":"CS1_maint:_Unfit_url"},{"sortkey":"","hidden":"","*":"Articles_with_incomplete_citations_from_July_2013"},{"sortkey":"","hidden":"","*":"All_articles_with_incomplete_citations"},{"sortkey":"","hidden":"","*":"CS1_maint:_BOT:_original-url_status_unknown"},{"sortkey":"","hidden":"","*":"All_articles_lacking_reliable_references"},{"sortkey":"","hidden":"","*":"Articles_lacking_reliable_references_from_September_2012"},{"sortkey":"","hidden":"","*":"Pages_using_web_citations_with_no_URL"},{"sortkey":"","hidden":"","*":"Articles_with_short_description"},{"sortkey":"","*":"Dietary_supplements"},{"sortkey":"","*":"Multi-level_marketing_products"},{"sortkey":"","*":"Multi-level_marketing_companies_based_in_Utah"},{"sortkey":"","*":"2003_establishments"},{"sortkey":"","*":"Salt_Lake_City"},{"sortkey":"","*":"Health_fraud"}],"links":[{"ns":14,"exists":"","*":"Category:Articles with incomplete citations from July 2013"},{"ns":14,"exists":"","*":"Category:Articles lacking reliable references from September 2012"},{"ns":14,"exists":"","*":"Category:CS1 maint: BOT: original-url status unknown"},{"ns":14,"exists":"","*":"Category:CS1 maint: Unfit url"},{"ns":0,"exists":"","*":"Amyotrophic lateral sclerosis"},{"ns":0,"exists":"","*":"Anti-aging"},{"ns":0,"exists":"","*":"Bacopa monnieri"},{"ns":0,"exists":"","*":"Cancer"},{"ns":0,"exists":"","*":"Catalase"},{"ns":0,"exists":"","*":"Chemical compound"},{"ns":0,"exists":"","*":"Chemins"},{"ns":0,"exists":"","*":"CortiSlim"},{"ns":0,"exists":"","*":"Deepak Chopra"},{"ns":0,"exists":"","*":"Denver Business Journal"},{"ns":0,"exists":"","*":"Denver Post"},{"ns":0,"exists":"","*":"Dietary supplement"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"FDA warning letter"},{"ns":0,"exists":"","*":"Federal Food, Drug, and Cosmetic Act"},{"ns":0,"exists":"","*":"Federal Trade Commission"},{"ns":0,"exists":"","*":"GNC (store)"},{"ns":0,"exists":"","*":"Glutathione peroxidase"},{"ns":0,"exists":"","*":"Green tea"},{"ns":0,"exists":"","*":"Harriet A. Hall"},{"ns":0,"exists":"","*":"Herbal"},{"ns":0,"exists":"","*":"Insider trading"},{"ns":0,"exists":"","*":"Joe M. McCord"},{"ns":0,"exists":"","*":"List of unproven and disproven cancer treatments"},{"ns":0,"exists":"","*":"Major League Soccer"},{"ns":0,"exists":"","*":"Metabolife"},{"ns":0,"exists":"","*":"Multi-level marketing"},{"ns":0,"exists":"","*":"Nutraceutical"},{"ns":0,"exists":"","*":"Over the counter"},{"ns":0,"exists":"","*":"Patent medicine"},{"ns":0,"exists":"","*":"Peptide"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"Pyramid scheme"},{"ns":0,"exists":"","*":"Quackery"},{"ns":0,"exists":"","*":"RICO Act"},{"ns":0,"exists":"","*":"Real Salt Lake"},{"ns":0,"exists":"","*":"Reuters"},{"ns":0,"exists":"","*":"SB Nation"},{"ns":0,"exists":"","*":"Salt Lake Tribune"},{"ns":0,"exists":"","*":"Science-Based Medicine (website)"},{"ns":0,"exists":"","*":"Science Based Medicine"},{"ns":0,"exists":"","*":"Securities and Exchange Commission"},{"ns":0,"exists":"","*":"Silybum marianum"},{"ns":0,"exists":"","*":"Superoxide dismutase"},{"ns":0,"exists":"","*":"The Scotsman"},{"ns":0,"exists":"","*":"Turmeric"},{"ns":0,"exists":"","*":"U.S. Food and Drug Administration"},{"ns":0,"exists":"","*":"U.S. Securities and Exchange Commission"},{"ns":0,"exists":"","*":"United States Securities and Exchange Commission"},{"ns":0,"exists":"","*":"Utah"},{"ns":0,"exists":"","*":"Withania somnifera"},{"ns":4,"exists":"","*":"Wikipedia:Citing sources"},{"ns":4,"exists":"","*":"Wikipedia:Independent sources"},{"ns":12,"exists":"","*":"Help:CS1 errors"}],"templates":[{"ns":10,"exists":"","*":"Template:Short description"},{"ns":10,"exists":"","*":"Template:Pagetype"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Cite patent"},{"ns":10,"exists":"","*":"Template:Citation/patent"},{"ns":10,"exists":"","*":"Template:Citation/make link"},{"ns":10,"exists":"","*":"Template:Citation/authors"},{"ns":10,"exists":"","*":"Template:Cite web"},{"ns":10,"exists":"","*":"Template:Cite news"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":10,"exists":"","*":"Template:Full citation needed"},{"ns":10,"exists":"","*":"Template:Fix"},{"ns":10,"exists":"","*":"Template:Category handler"},{"ns":10,"exists":"","*":"Template:Fix/category"},{"ns":10,"exists":"","*":"Template:Delink"},{"ns":10,"exists":"","*":"Template:Third-party-inline"},{"ns":10,"exists":"","*":"Template:Third-party inline"},{"ns":10,"exists":"","*":"Template:Cite press release"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":828,"exists":"","*":"Module:Pagetype"},{"ns":828,"exists":"","*":"Module:Pagetype/config"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:Yesno"},{"ns":828,"exists":"","*":"Module:Namespace detect"},{"ns":828,"exists":"","*":"Module:Namespace detect/data"},{"ns":828,"exists":"","*":"Module:Namespace detect/config"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Unsubst"},{"ns":828,"exists":"","*":"Module:Category handler"},{"ns":828,"exists":"","*":"Module:Category handler/data"},{"ns":828,"exists":"","*":"Module:Category handler/config"},{"ns":828,"exists":"","*":"Module:Category handler/shared"},{"ns":828,"exists":"","*":"Module:Category handler/blacklist"},{"ns":828,"exists":"","*":"Module:Delink"},{"ns":828,"exists":"","*":"Module:No globals"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"}],"images":[],"externallinks":["https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=US7241461","http://www.lifevantage.com/faqs/","https://sciencebasedmedicine.org/protandim-update-new-studies-and-an-fda-warning-letter/","http://www.sltrib.com/home/5221187-155/real-salt-lake-rsl-jersey-sponsor","http://www.rslsoapbox.com/2017/4/26/15436756/rsl-kit-sponsor-lifevantage-cancer-treatment-claims-fda-warning","https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2017/ucm554234.htm","http://www.highbeam.com/doc/1G1-112356866.html","http://www.prweb.com/releases/2004/12/prweb183718.htm","http://www.the-scientist.com/article/display/23192/#ixzz1DA5Ng18E","https://archive.is/20130414193633/http://www.cryonics.org/immortalist/january04/lifeline.htm","http://www.cryonics.org/immortalist/january04/lifeline.htm","https://web.archive.org/web/20041204092646/http://www.betterhumans.com/Features/Reports/report.aspx?articleID=2004-11-29-1","http://www.scotsman.com/news/scientist-returns-to-build-long-life-pill-plant-1-894387","http://business.highbeam.com/3563/article-1G1-111038316/denver-businessmen-gamble-selling-fountain-youth-pill","http://www.footnoted.com/uncategorized/some-days-its-just-hard-to-believe/","http://www.bizjournals.com/denver/stories/2005/07/04/daily12.html","https://www.sec.gov/Archives/edgar/data/849146/000102189005000208/lifeline1111058kex991.htm","https://www.sec.gov/Archives/edgar/data/849146/000102189005000106/lifeline720058kex99.htm","https://www.reuters.com/article/2008/01/14/idUS120817+14-Jan-2008+PRN20080114","https://web.archive.org/web/20111112065451/http://www.lifevantage.com/company/our-story/","http://www.lifevantage.com/company/our-story/","http://edgar.secdatabase.com/135/102189006000015/filing-main.htm","http://pdf.secdatabase.com/988/0001193125-11-258536.pdf","https://web.archive.org/web/20110304012432/http://secwatch.com/mccord-joe-m","http://secwatch.com/mccord-joe-m","https://www.sec.gov/Archives/edgar/data/849146/000119312511258536/d225491d10k.htm","https://www.sec.gov/Archives/edgar/data/849146/000119312511258536/d225491dex1031.htm","http://biz.yahoo.com/e/130625/lfvn8-k.html","https://www.ftc.gov/news-events/press-releases/2005/09/three-cortislim-defendants-give-45-million-cash-and-other-assets","https://globenewswire.com/news-release/2014/01/07/600765/10063209/en/LifeVantage-Corporation-Appoints-Shawn-Talbott-Ph-D-as-New-Global-Chief-Science-Officer.html","https://bestfutureyou.com/2015/07/13/my-new-gig/","http://www.google.com/patents/WO2015164504A1?cl=en","https://web.archive.org/web/20110721233521/http://www.lifevantage.com/products-breakthrough.aspx","http://youtube.googleapis.com/v/C5vli73g_CA&start=2303","http://www.blogtalkradio.com/lifevantage/blog/2009/03/09/inside-protandim-the-paul-myhill-interview","http://static.protandimscams.com/images/mccord-didnt-invent-protandim.jpg","//doi.org/10.1016/j.freeradbiomed.2008.10.050","//www.ncbi.nlm.nih.gov/pubmed/19056485","https://web.archive.org/web/20180424192807/https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm554777.htm","https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm554777.htm","https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26414415","//doi.org/10.3109/21678421.2015.1088707","//www.ncbi.nlm.nih.gov/pubmed/26414415","http://www.sciencebasedmedicine.org/index.php/pursued-by-protandim-proselytizers/","http://www.protandim.com/faqs","https://sciencebasedmedicine.org/i-was-wrong-about-protandim/","http://www.fda.gov/Safety/Recalls/ucm331258.htm","http://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?action=select&recall_number=F-0876-2013&w=01162013&lang=eng","http://edgar.secdatabase.com/2677/119312513053627/filing-main.htm","http://www.daily-times.com/ci_14059464","https://www.rosenlegal.com/cases-952.html","http://securities.stanford.edu/filings-documents/1059/LC00_02/2016915_f01c_16CV00965.pdf","https://globenewswire.com/news-release/2017/10/23/1151587/0/en/LifeVantage-Announces-Dismissal-of-Class-Action-Lawsuit.html","https://ecf.utd.uscourts.gov/cgi-bin/show_public_doc?216cv0965-51","https://www.businesswire.com/news/home/20180219005625/en/Sommers-Schwartz-P.C.-Announces-Filing-Securities-Class","https://www.rsl.com/post/2013/10/29/real-salt-lake-unveils-new-long-term-jersey-front-partnership-lifevantage","http://www.allbusiness.com/company-activities-management/board-management/5376294-1.html","http://globenewswire.com/news-release/2013/06/25/556132/10037495/en/Dr-Joe-McCord-LifeVantage-Corporation-s-First-Chief-Science-Officer-Retires-From-Company.html","http://www.lifevantage.com"],"sections":[{"toclevel":1,"level":"2","line":"History","number":"1","index":"1","fromtitle":"Protandim","byteoffset":1871,"anchor":"History"},{"toclevel":2,"level":"3","line":"Product invention","number":"1.1","index":"2","fromtitle":"Protandim","byteoffset":13160,"anchor":"Product_invention"},{"toclevel":1,"level":"2","line":"Composition","number":"2","index":"3","fromtitle":"Protandim","byteoffset":15283,"anchor":"Composition"},{"toclevel":1,"level":"2","line":"Effectiveness","number":"3","index":"4","fromtitle":"Protandim","byteoffset":16176,"anchor":"Effectiveness"},{"toclevel":1,"level":"2","line":"Side effects","number":"4","index":"5","fromtitle":"Protandim","byteoffset":17901,"anchor":"Side_effects"},{"toclevel":1,"level":"2","line":"Legal and regulatory issues","number":"5","index":"6","fromtitle":"Protandim","byteoffset":18492,"anchor":"Legal_and_regulatory_issues"},{"toclevel":2,"level":"3","line":"Protandim voluntary recall","number":"5.1","index":"7","fromtitle":"Protandim","byteoffset":18524,"anchor":"Protandim_voluntary_recall"},{"toclevel":2,"level":"3","line":"FDA Warning for illegal marketing of Protandim","number":"5.2","index":"8","fromtitle":"Protandim","byteoffset":19809,"anchor":"FDA_Warning_for_illegal_marketing_of_Protandim"},{"toclevel":2,"level":"3","line":"Other","number":"5.3","index":"9","fromtitle":"Protandim","byteoffset":20693,"anchor":"Other"},{"toclevel":1,"level":"2","line":"Promotional sponsorship","number":"6","index":"10","fromtitle":"Protandim","byteoffset":24565,"anchor":"Promotional_sponsorship"},{"toclevel":1,"level":"2","line":"See also","number":"7","index":"11","fromtitle":"Protandim","byteoffset":25447,"anchor":"See_also"},{"toclevel":1,"level":"2","line":"References","number":"8","index":"12","fromtitle":"Protandim","byteoffset":25531,"anchor":"References"},{"toclevel":1,"level":"2","line":"External links","number":"9","index":"13","fromtitle":"Protandim","byteoffset":25561,"anchor":"External_links"}],"parsewarnings":[],"displaytitle":"Protandim","iwlinks":[],"properties":[{"name":"wikibase-shortdesc","*":"American multi-level marketing company"},{"name":"wikibase_item","*":"Q7251172"}]}}